NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma Inc (NASDAQ:MEIP) issued its quarterly earnings data on Thursday, February, 6th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.11. The business earned $1.01 million during the quarter, compared to the consensus estimate of $1.24 million. MEI Pharma had a negative return on equity of 70.99% and a negative net margin of 825.55%. View MEI Pharma's Earnings History.

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for MEI Pharma.

2 equities research analysts have issued twelve-month price objectives for MEI Pharma's shares. Their forecasts range from $10.00 to $10.00. On average, they expect MEI Pharma's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 321.9% from the stock's current price. View Analyst Price Targets for MEI Pharma.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

Press coverage about MEIP stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MEI Pharma earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for MEI Pharma.

MEI Pharma saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 367,900 shares, an increase of 25.2% from the December 31st total of 293,800 shares. Based on an average daily trading volume, of 419,200 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the shares of the company are sold short. View MEI Pharma's Current Options Chain.

Some companies that are related to MEI Pharma include I-Mab (ARQT), Gossamer Bio (GOSS), Achillion Pharmaceuticals (ACHN), Applied Therapeutics (APLT), Cytokinetics (CYTK), Stoke Therapeutics (STOK), Radius Health (RDUS), Endonovo Therapeutics (ENDV), Amphastar Pharmaceuticals (AMPH), ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS) and Homology Medicines (FIXX).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Opko Health (OPK), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL) and Geron (GERN).

MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (8.38%), BVF Inc. IL (5.04%), Renaissance Technologies LLC (2.82%), State Street Corp (1.17%), Point72 Asset Management L.P. (0.80%) and Geode Capital Management LLC (0.74%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View Institutional Ownership Trends for MEI Pharma.

MEIP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, New York State Common Retirement Fund and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for MEI Pharma.

MEIP stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, NEA Management Company LLC, Point72 Asset Management L.P., Geode Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., State Street Corp and DAVENPORT & Co LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds. View Insider Buying and Selling for MEI Pharma.

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEIP stock can currently be purchased for approximately $2.37.

MEI Pharma has a market capitalization of $251.22 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

The official website for MEI Pharma is http://www.meipharma.com/.

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]